Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3

Cancer Research

Volumn 57, Issue 15, 1997, Pages 3238-3244

  Halder, Thomas ^a   Pawelec, Graham ^a   Kirkin, Alexei F ^b   Zeuthen, Jesper ^b   Meyer, Helmut E ^c   Kun, Li ^a   Kalbacher, Hubert ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; GLYCOPROTEIN; HLA DQ ANTIGEN; HLA DR3 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ARTICLE; DESORPTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MASS SPECTROMETRY; MELANOMA; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; ANNEXIN A2; ANTIGENS, NEOPLASM; CHO CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; HYDROGEN-ION CONCENTRATION; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; TUMOR CELLS, CULTURED;

EID: 0030802482     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Topalian, S. L. MHC class II restricted antigens and the role of CD4(+) T cells in cancer immunotherapy. Curr. Opin. Immunol., 6: 741-745, 1994.
2. Maeurer, M. J., Storkus, W. J., Kirkwood, J. M., and Lotze, M. T. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res., 6: 11-24, 1996.
3. Van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., de Plaen, E., and Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Washington DC). 254: 1643-1647, 1991.
4. Robbins, P. F., El-Gamil, M., Kawakami, Y., and Rosenberg, S. A. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res., 54: 3124-3126, 1994.
5. Rivoltini, L., Kawakami, Y., Sakaguchi, K., Southwood, S., Sette, A., Robbins, P. F., Marincola, F. M., Salgaller, M. L., Yanelli, Y. R., Appella, A., and Rosenberg, S. A. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lympho-cytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol., 154: 2257-2265, 1995.
6. Gaugler, B., van den Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J. J., de Plaen, E., Lethe, B., Brasseur F., and Boon, T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous T lymphocytes. J. Exp. Med., 179: 921-930, 1994.
7. Brichard, V., van Pel, A., Wölfel, T., Wölfel, C., de Plaen, E., Lethe, B., Coulie, P., and Boon, T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 17: 489-495, 1994.
8. Boon, T., Gajewski, T. F., and Coulie, P. G. From defined human tumor antigens to effective immunization. Immunol. Today, 16: 334-336, 1995.
9. Traversari, C., van der Bruggen, P., Luescher, I. F., Lurquin, C., Chomez, P., van Pel, A., de Plaen, E., Amar-Costesec, A., and Boon, T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1, by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med., 176: 1453-1458, 1992.
10. Van der Bruggen, P., Szikora, J-P., Boel, P., Wildmann, C., Somville, M., Sensi, M., and Boon, T. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*16018. Eur. J. Immunol., 24: 2134-2140, 1994.
11. Wölfel, T., van Pel, A., Brichard, V., Schneider, J., Seliger, B., and Meyer zum Büschenfelde, K-H. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol., 24: 759-764, 1994.
12. Boel, P., Wildmann, C., Sensi, M-L., Brasseur, R., Renauld, J-C., Coulie, P., Boon, T., and van der Bruggen, P. BAGE: a new gene encoding an antigen recognized on melanomas by cytolytic T lymphocytes. Immunity, 2: 167-175, 1995.
13. Wang, R-F., Robbins, P. F., Kawakami, Y., Kang, X-Q., and Rosenberg, S. A. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med., 181: 799-804, 1995.
14. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Appella, J., and Rosenberg, S. A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA, 91: 3515-3519, 1994.
15. Coulie, P. G., Brichard, V., van Pel, A., Wölfel, T., Schneider, J., Traversari, C., Mattei, S., de Plaen, E., Lurquin, C., and Szikora, J-P. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 180: 35-42, 1994.
16. + cytotoxic T lymphocytes. J. Exp. Med., 181: 363-368, 1995.
17. Bakker, A. B. H., Schreurs, M. W. J., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., and Figdor, C. G. Melanocyte lineage-specific gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med., 179: 1005-1009, 1994.
18. Bakker, A. B., Schreurs, M. W., Tafazzul, G., de Boer, A. J., Kawakami, Y., Adena, G. J., and Figdor, C. D. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.I-restricted anti-melanoma CTL line. Int. J. Cancer, 62: 97-102, 1995.
19. Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., and Slingluff, C. L., Jr. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science (Washington DC), 264: 716-719, 1994.
20. Salgaller, M. L., Afshar, A., Marincola, F. M., Rivoltini, L., Kawakami, Y., and Rosenberg, S. A. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res., 55: 4972-4979, 1995.
21. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med., 183: 1965-1971, 1996.